PMID- 35619702
OWN - NLM
STAT- MEDLINE
DCOM- 20220530
LR  - 20231101
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal 
      Cancer.
PG  - 887189
LID - 10.3389/fimmu.2022.887189 [doi]
LID - 887189
AB  - Dendritic cells (DCs), the strongest antigen-presenting cells, are a focus for 
      orchestrating the immune system in the fight against cancer. Basic scientific 
      investigations elucidating the cellular biology of the DCs have resulted in new 
      strategies in this fight, including cancer vaccinology, combination therapy, and 
      adoptive cellular therapy. Although immunotherapy is currently becoming an 
      unprecedented bench-to-bedside success, the overall response rate to the current 
      immunotherapy in patients with gastrointestinal (GI) cancers is pretty low. Here, 
      we have carried out a literature search of the studies of DCs in the treatment of 
      GI cancer patients. We provide the advances in DC-based immunotherapy and 
      highlight the clinical trials that indicate the therapeutic efficacies and 
      toxicities related with each vaccine. Moreover, we also offer the 
      yet-to-be-addressed questions about DC-based immunotherapy. This study focuses 
      predominantly on the data derived from human studies to help understand the 
      involvement of DCs in patients with GI cancers.
CI  - Copyright (c) 2022 Ni.
FAU - Ni, Ling
AU  - Ni L
AD  - Institute for Immunology and School of Medicine, Tsinghua University, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220510
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - *Dendritic Cells
MH  - *Gastrointestinal Neoplasms/therapy
MH  - Humans
MH  - Immunotherapy/methods
MH  - Immunotherapy, Adoptive
PMC - PMC9127253
OTO - NOTNLM
OT  - dendritic cells
OT  - gastrointestinal cancers
OT  - immunotherapy
OT  - patients
OT  - vaccines
COIS- The author declares that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/28 06:00
MHDA- 2022/05/31 06:00
PMCR- 2022/01/01
CRDT- 2022/05/27 02:15
PHST- 2022/03/01 00:00 [received]
PHST- 2022/04/08 00:00 [accepted]
PHST- 2022/05/27 02:15 [entrez]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/05/31 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.887189 [doi]
PST - epublish
SO  - Front Immunol. 2022 May 10;13:887189. doi: 10.3389/fimmu.2022.887189. eCollection 
      2022.